科研项目：
1.国家自然科学基金委员会，《MTA1转录因子通过调控破骨细胞分化干预骨质疏松症病理发生的分子机制》
2.中国博后基金会，《LFA-1联合ICAM-1调控RANKL介导破骨细胞分化机制研究》
3.中国博后基金会，《LFA/ICAM经cFos/NFATc调控破骨细胞分化及药物干预研究》
4.中国博后基金会，《ICAM-1通过NF-KB调控RANKL介导破骨细胞分化机制研究》
5.陕西省科技厅，《Syk经LFA-1/ICAM-1调控破骨细胞分化机制研究》
6.陕西省卫健委，《LFA-1通过NF-KB调控RANKL介导破骨细胞分化机制研究》
7.西安市卫健委，《炎性转录因子参与巨噬细胞向破骨细胞分化的分子机制研究》
8.西安交通大学，《致炎因子通过调控破骨细胞分化千预骨代谢异常发生的分子机制》
学术论文：
1.Zhang J, Feng M, Kong L*. The Therapeutic Potential of Melatonin in Alzheimer's Disease: A Comprehensive Review. Curr Med Chem. Published online March 28, 2024.
2.Feng M, Liu L, Qu Z, Kong L*et al. CRISPR/Cas9 knockout of MTA1 enhanced RANKL-induced osteoclastogenesis in RAW264.7 cells partly via increasing ROS activities. J Cell Mol Med. 2023;27(5):701-713. doi:10.1111/jcmm.17692
3.Kong L#. Commentary on "Established and Emerging Therapies in Acute Spinal Cord Injury". Neurospine. 2022;19(2):297-298. doi:10.14245/ns.2244486.243
4.Kong L#. Current Study of Natural Products for Medicinal Chemistry. Curr Med Chem. 2021;28(25):5189-5190. doi:10.2174/092986732825210816114755
5.Huang W#, Kong L#, Cao Y, Yan L. Identification and Quantification, Metabolism and Pharmacokinetics, Pharmacological Activities, and Botanical Preparations of Protopine: A Review. Molecules. 2021;27(1):215. Published 2021 Dec 30. doi:10.3390/molecules27010215
6.Kong L#, Ma R, Cao Y, et al. Cell cytoskeleton and proliferation study for the RANKL-induced RAW264.7 differentiation. J Cell Mol Med. 2021;25(10):4649-4657. doi:10.1111/jcmm.16390
7.Li D, Liu Y, Yang X, Kong L*. The Role of Probiotics and Prebiotics in Osteolastogenesis and Immune Relevance. Curr Med Chem. 2021;28(25):5228-5247. doi:10.2174/0929867328666210316115126
8.Li T, Ning B, Kong L*, et al. A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts. Cells. 2021;10(2):480. Published 2021 Feb 23. doi:10.3390/cells10020480
9.Yang B, Kong L*, Hao D*. Challenges in the Management of Pregnancy and Lactation Associated Osteoporosis: Literature Review and Retrospective Study. Curr Stem Cell Res Ther. 2021;16(6):688-694. doi:10.2174/1574888X15999200729162502
10.Kong L*. Plant-Derived Compounds in Regulating Bone Stem Cells. Curr Stem Cell Res Ther. 2020;15(1):3. doi:10.2174/1574888X1501200206121632
11.Liu Y, Dou Y, Lingbo K* et al. The role of Rho GTPases' substrates Rac and Cdc42 in osteoclastogenesis and relevant natural medicinal products study. Biosci Rep. 2020;40(7):BSR20200407. doi:10.1042/BSR20200407
12.Chang Z, Wang Y, Liu C, Smith W, Kong L*. Natural Products for Regulating Macrophages M2 Polarization. Curr Stem Cell Res Ther. 2020;15(7):559-569. doi:10.2174/1574888X14666190523093535
13.Cao Y, Smith W, Yan L, Kong L*. Overview of Cellular Mechanisms and Signaling Pathways of Piceatannol. Curr Stem Cell Res Ther. 2020;15(1):4-10. doi:10.2174/1574888X14666190402100054
14.Liu C, He Y, Xu X, He L, He B, Kong L*. The Study of Natural Compounds Targeting RANKL Signaling Pathway for the Treatment of Bone Diseases. Curr Drug Targets. 2020;21(4):344-357. doi:10.2174/1389450120666190930145144
15.Kong L*. Current Study and Novel Understanding for Macrophages. Curr Stem Cell Res Ther. 2020;15(7):557-558. doi:10.2174/1574888X1507200810094100
16.Liu Y#, He Y, Baorong H, Lingbo K*. The Anti-osteoporosis Effects of Natto on Bone Mineral Density in Perimenopausal Women. Curr Med Chem. 2020 Mar 6. doi:10.2174/0929867327666200306123140.
17.Kong L#，*, Wang B, Yang X, He B, Hao D, Yan L*. Integrin-associated molecules and signalling cross talking in osteoclast cytoskeleton regulation. J Cell Mol Med. 2020 Feb 11. doi: 10.1111/jcmm.15052.
18.Kong L#, Yang X*. Study of Intercellular Adhesion Molecule-1 (ICAM-1) in Bone Homeostasis. Curr Drug Targets. 2020;21(4):328-337.
19.Yang X#, Zheng H, Liu Y, Hao D, He B, Kong L*. Puerarin for OVX-Induced Postmenopausal Osteoporosis in Murine Model: Systematic Review and Meta-Analysis. Curr Stem Cell Res Ther. 2020;15(1):37-42.
20.Xiao Y#, Cao Y#, Song C#, Ren X, Yan L, Hao D*, Kong L*. Cellular study of the LPS-induced osteoclastic multinucleated cell formation from RAW264.7 cells. J Cell Physiol. 2020 Jan;235(1):421-428. doi: 10.1002/jcp.28982.
21.Kong L#,*, Smith W, Hao D. Overview of RAW264.7 for osteoclastogensis study: Phenotype and stimuli. J Cell Mol Med. 2019 May;23(5):3077-3087.
22.Zhang Z#, Wen H, Yang X, Zhang K, He B, Zhang X, Kong L*. Stimuli and Relevant Signaling Cascades for NFATc1 in Bone Cell Homeostasis: Friend or Foe? Curr Stem Cell Res Ther. 2019;14(3):239-243.
23.Song C#, Yang X#, Lei Y#, Zhang Z, Smith W, Yan J, Kong L*.Evaluation of efficacy on RANKL induced osteoclast from RAW264.7 cells. J Cell Physiol. 2019 Jul;234(7):11969-11975.
24.Wang Y, Smith W, Hao D, He B, Kong L*. M1 and M2 macrophage polarization and potentially therapeutic naturally occurring compounds. Int Immunopharmacol. 2019;70:459-466. doi:10.1016/j.intimp.2019.02.050
25.Kong L#, Wang Y, Smith W, Hao D. Macrophages in Bone Homeostasis. Curr Stem Cell Res Ther. 2019;14(6):474-481. doi:10.2174/1574888X14666190214163815
26.Wang B, Wen H, Smith W, Hao D, He B, Kong L*. Regulation effects of melatonin on bone marrow mesenchymal stem cell differentiation. J Cell Physiol. 2019;234(2):1008-1015. doi:10.1002/jcp.27090
27.Wang B#, Hao D#, Zhang Z, Gao W, Pan H, Xiao Y, He B, Kong L*.Inhibition effects of a natural inhibitor on RANKL downstream cellular signalling cascades cross-talking. J Cell Mol Med. 2018 Sep;22(9):4236-4242.
获 奖：
1.2019年获陕西省政府“骨质疏松性脊柱骨折精准化诊疗新体系的创立于推广”奖，排名2/11
专 利：
1.一种流式细胞鞘液细胞无间断灌注装置，专利保护期（2017.05-2027.05）
2.一种新型骨科脊柱损伤治疗椅，专利保护期（2017.05-2027.05）
3.腰椎后路椎间融合系统，专利保护期（2020.07-2030.07）
4.一种椎体骨水泥注射装置，专利保护期（2020.07-2030.07）
5.一体式靶向椎体后凸成形系统，专利保护期（2020.07-2030.07）
6.骨修复材料及其制备方法，专利保护期（2018.12-2028.12 |
